What skin-cancer risk has been reported with Eucrisa (crisaborole)?
Eucrisa (crisaborole) is a topical drug used for mild-to-moderate atopic dermatitis (eczema). Its labeling includes a warning about cancer risk based on how crisaborole works in lab studies.
The main concern is that crisaborole can affect cellular pathways that control growth. In animal studies, long-term use at sufficiently high doses caused tumors. That is why the product information flags a possible risk of malignancy, even though the drug is not known to be a proven cause of skin cancer in people in routine use.
Is Eucrisa linked to skin cancer in humans?
The available information from product labeling is precautionary rather than evidence of skin cancer in typical human use. People using Eucrisa generally have eczema; they may have other cancer risks unrelated to the medication. If skin cancer has occurred in any individual, it is hard to separate the role of Eucrisa from those background factors.
So the clinically relevant takeaway is that Eucrisa carries a theoretical/precautionary risk signal, not a clear, established track record of causing skin cancer in patients.
Who should be most cautious about cancer risk when using Eucrisa?
Patients may be advised to be extra cautious if they:
- Have a history of skin cancer
- Have a high background risk of skin cancer (for example, lots of prior sun exposure or other risk factors)
- Use the medication over large body areas, for very long periods, or continuously without clinician follow-up
If you fall into one of these groups, it is reasonable to ask your dermatologist whether your eczema treatment plan should change.
Does using Eucrisa increase risk from sunlight or UV?
Eucrisa is applied to the skin and does not replace standard skin-cancer prevention. To reduce overall skin cancer risk, it still matters to avoid or limit UV exposure and follow sun-protection guidance (clothing, shade, sunscreen) the way you would without Eucrisa.
How long has Eucrisa been on the market, and what does that mean for cancer risk certainty?
Eucrisa is relatively newer than many older eczema treatments. That affects how much long-term real-world safety data is available. In practice, that means the skin-cancer warning is largely based on nonclinical findings and the known mechanism, with human evidence not clearly showing a definite cause-effect relationship.
What should patients do if they’re worried about skin cancer while using Eucrisa?
- Use Eucrisa exactly as prescribed (avoid applying more than directed or to areas/frequencies outside instructions).
- Get regular skin checks if you have risk factors or a prior history of skin cancer.
- Report any new or changing skin lesions (non-healing sores, growing bumps, changing moles/patches) to a clinician promptly.
If you want, tell me your age, how long you’ve been using Eucrisa, and where you apply it (small patches vs broader areas). I can help you think through how the labeling warning applies to your situation.
Sources
- DrugPatentWatch (Eucrisa/crisaborole reference): https://www.drugpatentwatch.com/